Sugi Predict

Sugi Predict / Compounds / SCHEMBL709085

SCHEMBL709085

SCHEMBL709085

C[Si](C)(C)C#Cc1ccccc1C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.44
▸ LMNA P02545 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.42
▸ TSHR P16473 2/20 0.42
▸ HPGD P15428 2/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TRIM24 O15164 2/20 0.38
▸ TRIM33 Q9UPN9 2/20 0.38
▸ CREBBP Q92793 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30408149 0.82 CREBBP (0.35) KMT2ALMNAMEN1THRBBLM
SCHEMBL28422107 0.82 ERN1 (0.37) KMT2ALMNAMEN1THRBBLM
SCHEMBL24216938 0.82 CREBBP (0.35) KMT2ALMNAMEN1THRBBLM
SCHEMBL28451124 0.81 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1TSHRHPGD
SCHEMBL31006274 0.80 LMNA (0.40) KMT2ALMNAMEN1THRBBLM
SCHEMBL3839029 0.79 KDM4E (0.49) KMT2AMEN1ALDH1A1TSHRHPGD
SCHEMBL6516855 0.78 CREBBP (0.39) KMT2ALMNAMEN1TDP1ALDH1A1
SCHEMBL9699037 0.78 LMNA (0.50) KMT2ALMNAMEN1THRBBLM
SCHEMBL2566365 0.77 CYP2A6 (0.34) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL5800613 0.77 ERN1 (0.33) KMT2AMEN1ALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113603682-B Dicyanomethylene-4H-pyran molecules with AIE effect, construction method and application 华东理工大学 2024-07-26 — — CN claimed
CN-117924116-A Preparation method and application of compound with compression color-changing property 天津理工大学 2024-04-26 — — CN claimed
US-12187681-B2 Ion channel antagonists/blockers and uses thereof SHANGHAI EAST HOSPITAL (CN) 2025-01-07 — — US disclosed
CN-113603682-B Dicyanomethylene-4H-pyran molecules with AIE effect, construction method and application 华东理工大学 2024-07-26 — — CN disclosed
US-20240151993-A1 ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS META PLATFORMS TECHNOLOGIES, LLC 2024-05-09 — — US disclosed
CN-117924116-A Preparation method and application of compound with compression color-changing property 天津理工大学 2024-04-26 — — CN disclosed
CN-114401935-B Ion channel antagonists/blockers and uses thereof 上海市东方医院（同济大学附属东方医院） 2024-04-05 — — CN disclosed
CN-114133336-B 4-methoxy naphthalene substituted aniline compound and preparation method and application thereof 沈阳药科大学 2024-04-02 — — CN disclosed
US-20230015875-A1 Ion Channel Antagonists/Blockers and Uses Thereof SHANGHAI EAST HOSPITAL (CN) 2023-01-19 — — US disclosed
US-20230015875-A1 Ion Channel Antagonists/Blockers and Uses Thereof SHANGHAI EAST HOSPITAL (CN) 2023-01-19 — — US disclosed
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2022-05-10 — — US disclosed
WO-2013173382-A1 BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN AMGEN INC. (US) 2013-11-21 — — WO disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 — — US disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 — — US disclosed
EP-2346807-A1 NAPHTHYLACETIC ACIDS F. Hoffmann-La Roche AG (CH) 2011-07-27 — — EP disclosed
EP-2193132-A2 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 2010-06-09 — — EP disclosed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 — — US disclosed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 — — US disclosed
WO-2010055005-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 — — WO disclosed
WO-2009004382-A2 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2009-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137250-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 KMT2A 2084/4885LMNA 1330/4885MEN1 3010/4885
US-20240151993-A1 ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS AR, OR10J3, ESRRG KMT2A 2389/4885LMNA 3078/4885MEN1 4718/4885
US-20230015875-A1 Ion Channel Antagonists/Blockers and Uses Thereof CACNA1F, CACNA1S, CACNA1D KMT2A 3777/4885LMNA 1041/4885MEN1 2638/4885
US-12187681-B2 Ion channel antagonists/blockers and uses thereof CACNA1F, CACNA1S, CACNA1D KMT2A 3777/4885LMNA 1041/4885MEN1 2638/4885
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor HDGF, F11, F12 KMT2A 3974/4885LMNA 826/4885MEN1 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.